ERBB2 and breast cancer: We find that proliferation drives prognosis in ER+ breast cancer, while pathways related to hypoxia, angiogenesis, development, and expression of extracellular matrix-associated proteins drive prognosis in ER−/HER2− and HER2+ breast cancer and ovarian cancer.